FDA Clears Next-Generation Guide Wire for Cardiovascular Systems' Peripheral Orbital Atherectomy Systems
ViperWire Advance Peripheral Guide Wire with Flex
Tip Offers Greater Flexibility and Navigation; Improves Systems’ Ease-of-Use
When Treating Calcified Lesions in Torturous Arterial Anatomy
ST. PAUL, Minn.-- Cardiovascular Systems, Inc., today announced that it has received FDA clearance for its new ViperWire Advance® Peripheral Guide Wire with Flex Tip for their Peripheral Orbital Atherectomy Systems (OAS). The new guide wire provides physicians with improved flexibility, navigation and ease-of-use—particularly in hard-to-reach, tortuous vessels—when treating arterial calcium associated with peripheral artery disease (PAD).
Building on the success of the current ViperWire Advance, this next-generation wire offers a reduction in tip stiffness, with comparable torque transfer, making it easier for physicians to navigate vasculature. The guide wire also provides improved trackability through tortuous peripheral arteries.
Additional features and enhancements of the ViperWire Advance Guide Wire with Flex Tip include:
- A Nitinol support coil, for a more durable tip and the ability to be reshaped for multiple uses; and
- Larger proximal core, for improved kink resistance and more delivery support for adjunctive devices.
“We designed the ViperWire Advance with Flex Tip to improve ease-of-use for our peripheral orbital atherectomy systems when treating complex calcified lesions,” said David L. Martin, CSI president and chief executive officer. “By improving the predictability and deliverability of the guide wire, physicians will now have more confidence in their ability to navigate tortuous peripheral anatomy and address PAD in a traditionally difficult-to-treat patient population.”
CSI anticipates launching ViperWire Advance with Flex Tip in early August 2015. The guide wire is for use with CSI’s 145 cm Stealth 360® and Diamondback 360® Peripheral OAS.
About Peripheral
Arterial Disease (PAD)
As many as 18 million Americans, most over age 65, suffer from PAD, which is
caused by plaque accumulation in peripheral arteries (commonly the pelvis or
leg) reducing blood flow. Symptoms include leg pain when walking or at rest.
Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and
eventually limb amputation. With risk factors such as diabetes and obesity on
the rise, the prevalence of PAD continues to grow.
Millions of patients with PAD may benefit from treatment with orbital atherectomy utilizing the Stealth 360® and Diamondback 360 Peripheral Orbital Atherectomy Systems, minimally invasive catheter systems developed and manufactured by CSI. These systems use a diamond-coated crown, attached to an orbiting shaft, which sands away plaque while preserving healthy vessel tissue—a critical factor in preventing reoccurrences. Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions. Stents are prone to fractures and high recurrence rates in calcified lesions, and treatment of hard, calcified lesions often leads to vessel damage and suboptimal results.
About Stealth 360® and
Diamondback 360®
The
Stealth 360® and Diamondback 360® Peripheral Orbital Atherectomy Systems are percutaneous orbital
atherectomy systems indicated for use as therapy in patients with occlusive
atherosclerotic disease in peripheral arteries and stenotic material from
artificial arteriovenous dialysis fistulae. The systems are contraindicated for
use in coronary arteries, bypass grafts, stents or where thrombus or
dissections are present. Although the incidence of adverse events is rare,
potential events that can occur with atherectomy include: pain, hypotension,
CVA/TIA, death, dissection, perforation, distal embolization, thrombus
formation, hematuria, abrupt or acute vessel closure, or arterial spasm.
Source: Cardiovascular Systems, Inc.
Comments